PDP1 and diabetic cardiomyopathy: Similarly, the glucagon-like peptide-1 receptor agonist liraglutide, an antidiabetic agent that promotes insulin secretion, also stimulates myocardial PDH activity and glucose oxidation, thereby alleviating the diastolic dysfunction in a murine model of diabetic cardiomyopathy (29).